Can Biktarvy Affect Kidney Function?
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has minimal impact on true kidney function, though bictegravir causes a benign increase in serum creatinine without affecting actual glomerular filtration rate. The tenofovir alafenamide (TAF) component is significantly safer for the kidneys than the older tenofovir disoproxil fumarate (TDF) formulation 1.
Understanding the Creatinine Effect vs. True Renal Toxicity
Bictegravir blocks tubular secretion of creatinine, resulting in a small (approximately 10%) increase in serum creatinine and calculated eGFR, but this does not represent actual kidney damage 1. This is a pharmacologic effect on creatinine handling, not true nephrotoxicity—the actual glomerular filtration rate remains unchanged.
Clinical Trial Safety Data
The evidence strongly supports Biktarvy's renal safety profile:
- In phase 3 trials with 2,635.6 patient-years of follow-up, there were zero cases of proximal renal tubulopathy or discontinuations due to renal events 1
- An integrated analysis of 1,069 people with HIV-1 and mild to moderate baseline renal impairment across 9 trials showed renal function remained generally stable over up to 240 weeks of treatment 2
- Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare 2
Comparison to Older Tenofovir Formulations
The TAF component in Biktarvy is substantially safer than TDF:
- TAF causes minimal eGFR decline (-0.3 mL/min) compared to TDF (-5.0 mL/min) in patients with renal risk factors 3
- When patients switch from TDF-containing regimens to Biktarvy, renal function typically improves: Chinese patients showed eGFR increases of +3.6 mL/min at 96 weeks post-switch 4
- TAF has much lower plasma concentrations than TDF, reducing systemic exposure and renal toxicity risk
Important Caveats and Monitoring
Postmarketing Renal Events
The FDA label warns that postmarketing cases of renal impairment, including acute renal failure, have been reported 5. Patients should avoid concurrent or recent use of nephrotoxic agents.
Rare Complication: Lactic Acidosis
A case report documented severe lactic acidosis (lactate 21.8 mmol/L) in a patient with chronic kidney disease on Biktarvy, requiring discontinuation and renal replacement therapy 6. This is extremely rare but potentially life-threatening, particularly in patients with pre-existing renal impairment.
Use in Severe Renal Impairment
- Biktarvy can be used in patients with creatinine clearance ≥30 mL/min without dose adjustment 7
- TAF is not recommended when creatinine clearance is <15 mL/min without dialysis 3
- Case reports suggest Biktarvy may be used in end-stage renal disease patients on hemodialysis, though this is off-label 8
Clinical Recommendations
For patients with normal renal function: Biktarvy poses minimal renal risk and requires no special monitoring beyond standard care 1.
For patients with renal risk factors (eGFR <60, proteinuria, diabetes, hypertension): Biktarvy remains a preferred option over TDF-containing regimens 3. Monitor renal function, but expect stability or improvement if switching from TDF.
For patients with eGFR 30-50 mL/min: Biktarvy is the first non-boosted integrase inhibitor-based single-tablet regimen suitable for this population 7.
Avoid Biktarvy when: Creatinine clearance is <30 mL/min (unless on dialysis with careful monitoring), or when concurrent nephrotoxic agents cannot be avoided 5.
Monitor for: Changes in serum creatinine (expect small benign increase from bictegravir), proteinuria, and symptoms of lactic acidosis (nausea, vomiting, abdominal pain, weakness) especially in patients with renal impairment 5, 6.